CSNK1A1 and cancer: In agreement, we observed more robust degradation of CK1α upon lenalidomide and other IMiD treatments in MV4.11 cells compared with DLD-1 cells (Fig S6A and B) or a panel of other cancer cell lines (Figs 1 and S1).